Results
Strides Pharma Q1 FY27 Revenue Up 13% YoY
Strides reported 13% YoY revenue growth to ₹12.16B, with Ex-US markets surging 17% YoY.
EBITDA margin held at 18.2% despite absorbing ₹131M in geopolitical-related freight and operating costs.
US reve
